Senseonics (NYSE:SENS) Hits New 52-Week High – What’s Next?

Senseonics Holdings, Inc. (NYSE:SENS)’s stock price reached a new 52-week high on Wednesday . The stock traded as high as $1.20 and last traded at $1.19, with a volume of 3529592 shares trading hands. The stock had previously closed at $1.10.

Analysts Set New Price Targets

Several equities analysts recently weighed in on SENS shares. HC Wainwright restated a “buy” rating and set a $2.00 target price on shares of Senseonics in a report on Friday, November 15th. StockNews.com initiated coverage on shares of Senseonics in a report on Thursday, December 26th. They issued a “sell” rating on the stock.

Senseonics Stock Up 11.4 %

The company has a debt-to-equity ratio of 59.17, a current ratio of 2.47 and a quick ratio of 2.38. The stock’s fifty day simple moving average is $0.65 and its 200-day simple moving average is $0.46. The stock has a market cap of $729.28 million, a P/E ratio of -9.42 and a beta of 0.69.

Insiders Place Their Bets

In other Senseonics news, CFO Frederick T. Sullivan purchased 124,933 shares of the stock in a transaction dated Thursday, December 12th. The shares were bought at an average cost of $0.38 per share, with a total value of $47,474.54. Following the completion of the acquisition, the chief financial officer now owns 2,478,844 shares of the company’s stock, valued at approximately $941,960.72. This trade represents a 5.31 % increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Timothy T. Goodnow purchased 315,000 shares of the stock in a transaction dated Tuesday, December 10th. The shares were acquired at an average cost of $0.31 per share, for a total transaction of $97,650.00. Following the completion of the acquisition, the chief executive officer now directly owns 11,310,355 shares of the company’s stock, valued at approximately $3,506,210.05. This trade represents a 2.86 % increase in their position. The disclosure for this purchase can be found here. 3.60% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the company. FMR LLC boosted its stake in Senseonics by 48,267.2% during the third quarter. FMR LLC now owns 168,318 shares of the company’s stock valued at $59,000 after buying an additional 167,970 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Senseonics by 3.2% in the 3rd quarter. Geode Capital Management LLC now owns 5,838,396 shares of the company’s stock valued at $2,042,000 after purchasing an additional 179,103 shares during the period. GSA Capital Partners LLP acquired a new position in shares of Senseonics in the 3rd quarter valued at $117,000. Cubist Systematic Strategies LLC boosted its position in shares of Senseonics by 25.9% in the 2nd quarter. Cubist Systematic Strategies LLC now owns 415,404 shares of the company’s stock valued at $166,000 after purchasing an additional 85,501 shares during the period. Finally, Ridgecrest Wealth Partners LLC acquired a new position in shares of Senseonics in the 4th quarter valued at $60,000. Institutional investors own 12.36% of the company’s stock.

About Senseonics

Senseonics Holdings, Inc, a medical technology company, focuses on development and manufacturing of continuous glucose monitoring (CGM) systems for people with diabetes in the United States and internationally. The company's products include Eversense, Eversense XL, and Eversense E3 that are implantable CGM systems to measure glucose levels in people with diabetes through an under-the-skin sensor, a removable and rechargeable smart transmitter, and a convenient app for real-time diabetes monitoring and management.